Aravive opens enrollment in phase Ib/II study of AVB-S6-500 in clear cell renal cell carcinoma Dec. 15, 2020
Novel potent PI3Kdelta inhibitors that target two different mechanisms of isoform selectivity Dec. 14, 2020
RSS